
	News & Events 2011-12-23 The first patient in the Phase III double blind COLLECT study has been randomized and treated at a clinic in Hungary. 2011-12-19 Phase III COLLECT study now opened. For more information about the study, please visit: Read more... 2011-11-23 InDex Pharmaceuticals launches a new website. 2011-10-24 InDex Pharmaceuticals participates at the UEGW (19th United European Gastroenterology Week) at Stockholmsmässan Oct 24-26. 2011-07-07 InDex Pharmaceuticals names Jesper Wiklund Chief Executive Officer. Read more... 2011-05-17 InDex Pharmaceuticals participates in the Swedish Congress Svenska Gastrodagarna in Umeå May 17-20, 2011. 2011-01-21 InDex Pharmaceuticals completes SEK 75m finance round. Read more... 2010-05-17 Index Pharmaceuticals is present with a booth in the yearly congress Svenska Gatrodagarna in Stockholm 17-20 May, 2010. 2009-12-08 Stockholms läns landsting introduces diagnostic test for patients with inflammatory bowel disease. Read more... 2009-11-11 Patent for the diagnostic test DiBiCol granted in Japan. Read more... 2009-05-18 Based on positive Phase II Results InDex Pharmaceuticals terminates Kappaproct study in advance. Read more... 2009-03-19 Last patient recruited in a Phase II study of Kappaproct. Read more... 2008-11-05 InDex Pharmaceuticals AB has filed five more patents that will further strengthen its extensive portfolio of proprietary intellectual assets. Read more...
InDex Pharmaceuticals AB, Scheeles väg 2, 171 77 Stockholm, Phone: +46 8 508 847 30, Fax: +46 8 508 847 39, info@indexpharma.com Copyright © 2011 InDex Pharmaceuticals AB. All Rights Reserved.